JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Efficacy and Safety of Topical Application of Epidermal Growth Factor (EGF) for Korean Acne Patient
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Efficacy and Safety of Topical Application of Epidermal Growth Factor (EGF) for Korean Acne Patient
Suh, Joon Hyuk; Hyun, Moo Yeol; Jang, Seong Eum; Choi, Sun Young; Kim, Myeung Nam; Kim, Beom Joon;
  PDF(new window)
 Abstract
Acne vulgaris is a chronic inflammatory condition characterized by comedo, papule, cyst, nodule and postinflammatory hyperpigmentation. Meanwhile, it is also induced by adverse event of drugs. Among them, acneiform folliculitis is a side effect of epidermal growth factor receptor (EGFR) inhibitor, which is an anticancer agent, and its incidence may occur in upward of 75 ~ 100% of cases. The main method of acne vulgaris treatment is oral antibiotics, retinoids, topical medication and so on. However, it is limitation that teratogenicity caused by retinoids and antibiotic resistance increased by using antibiotics. In this study, we aimed to evaluate the clinical efficacy and safety of topical recombinant human (rh) EGF in treating facial acne vulgaris. Twenty three Koreans (age: 10 ~ 29 years) with mild to moderate acne vulgar participated in the study and applied topical rhEGF cream (trouble control EGF) with 3 products (trouble control clarifying cleansing foam, trouble control all-clear filling toner, redroll calming moisture) on their face twice daily for four weeks. Several assessment methods were applied: Acne lesion counts score by investigator`s global assessment, efficacy and satisfaction score by subjects. Skin sebum output level, hydration level and redness level were also measured at each visit. At the final visit, skin sebum level, transepidermal water loss, skin redness statistically decreased and acne lesions (comedone, papule) were statistically reduced. No severe side effects were observed during the study. In conclusion, topical rhEGF seems to be an effective and safe adjuvant treatment option for mild acne vulgaris.
 Keywords
acne vulgaris;epidermal growth factor;EGF;recombinant human EGF;
 Language
Korean
 Cited by
 References
1.
B. K. Ahn, S. J. Lee, K. Namkoong, Y. L. Chung, and S. H. Lee, Quality of life of acne patients, Korean J. Dermatol., 43(1), 6 (2005).

2.
A. Zaenglein, E. Graber, and D. Thiboutot, Acne vulgaris and acneiform eruptions, in : Fitzpatrick's dermatology in general medicine, eds. K. Wolff, L. Goldsmith, S. Katz, B. Gilchrest, A. Paller, and D. Leffell, 897, McGraw-Hill, New York (2008).

3.
A. Wollenberg, J. Kroth, A. Hauschild, and T. Dirschka, Cutaneous side effects of EGFR inhibitors-appearance and management, Dtsch. Med. Wochenschr., 135(4), 149 (2010). crossref(new window)

4.
K. Busam, P. Capodieci, R. Motzer, T. Kiehn, D. Phelan, and A. Halpern, Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225, British J. Dermatol., 144(6), 1169 (2001). crossref(new window)

5.
T. Sato, N. Imai, and N. Akimoto, Epidermal growth factor and 1&agr;, 25-dihydroxyvitamin D3 suppress lipogenesis in hamster sebaceous gland cells in vitro, J. Invest. Dermatol., 117(4), 965 (2001). crossref(new window)

6.
J. U. Shin, J. H. Park, B. C. Cho, and J. H. Lee, Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor, Dermatology, 225(2), 135 (2012). crossref(new window)

7.
S. Cohen, Isolation of mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new born animal, J. Biol. Chem., 237(5), 1555 (1962).

8.
M. L. Kmiec, A. Pajor, and G. Broniarczyk-Dyla, Evaluation of biophysical skin parameters and assessment of hair growth in patients with acne treated with isotretinoin, Postepy. Dermatol. Alergol., 30(6), 343 (2013).

9.
M. R. Lee, C. B. Jeong, J. Y. Chul, H. K. Kim, and G. W. Nam, Correlation between skin translucency and scattering reflection using miniaturized new optical device, J. Soc. Cosmet. Sci. Kor., 37(2), 121 (2011).

10.
T. R. Mathanda, M. Bhat, R. P. Hegde, and S. Anand, Transepidermal water loss in neonates: baseline values using a closed-chamber system, Pediatr. Dermatol., 33(1), 33 (2016). crossref(new window)

11.
S. I. Jang, E. J. Kim, H. Park, H. J. Kim, J. M. Suk, B. J. Kim, J. H. Lee, and H. K. Lee, A quantitative evaluation method using processed optical images and analysis of age-dependent changes on nasolabial lines, Skin Res. Technol., 21(2), 201 (2015). crossref(new window)

12.
L. Nanney, Epidermal and dermal effect of epidermal growth factor during wound repair, J. Invest. Dermatol., 94(5), 624 (1990). crossref(new window)

13.
J. Baselag, Why the epidermal growth factor receptor? The rationale for cancer therapy, Oncologist., 7(4), 2 (2002).

14.
H. K. Kim, I. K. Yeo, K. Li, B. J. Kim, M. N. Kim, and C. K. Hong, Topical epidermal growth factor for the improvement of acne lesions: a randomized, double-blinded, placebo-controlled, split-face trial, Int. J. Dermatol., 53(8), 1031 (2014). crossref(new window)

15.
R. S. Stern, When a uniquely effective drug is teratogenic, N. Engl. J. Med., 320(15), 1007 (1989). crossref(new window)